MedPath

Multi-institutional observational research of therapeutic evaluation with minimal residual disease(MRD) after consolidation for multiple myeloma

Not Applicable
Conditions
Multiple myeloma
Registration Number
JPRN-UMIN000032970
Lead Sponsor
Ochanomizu Hematology Study Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
4
Inclusion Criteria

Not provided

Exclusion Criteria

Patient who is judged to be medically unfit by physician.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The MRD negative rate by evaluating multiparameter flow cytometry(MFC) after consolidation therapy.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath